Loading...
Docoh

Guided Therapeutics (GTHP)

Filed: 18 Aug 21, 1:22pm
 

  UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q/A
Amendment No. 1
 
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934
 
For the quarterly period ended March 31, 2021
Commission File No. 0-22179
  
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 
 Delaware
 
 58-2029543
 (State or other jurisdiction of incorporation or organization)
 
 (I.R.S. Employer Identification No.)
 
5835 Peachtree Corners East, Suite D
Norcross, Georgia 30092
(Address of principal executive offices) (Zip Code)
 
(770) 242-8723
(Registrant’s telephone number, including area code)     
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [X ] No[ ]
 
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):
 
Large Accelerated filer [  ]
Accelerated filer [   ]
Non-accelerated filer [ ]Smaller reporting company  [X]
 
Emerging growth company [   ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13 (a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes [ ] No [X] 
 
As of May 17, 2021, the registrant had 13,278,417 shares of common Stock, $0.001 par value per share, outstanding.
 

 
 
  
GUIDED THERAPEUTICS, INC. 
 
EXPLANATORY NOTE
 
This Amendment No. 1 on Form 10-Q/A is filed solely to amend and restate sections in Part I of Item 1 and 2 of the Form 10-Q for the quarter ended March 31, 2021, which was filed on May 21, 2021 (the “Form 10-Q”), due to a clerical error in the authorized number of shares available for the Series F preferred shares. The Company was only authorized to issue 1,500 and not 5,000 of the Series F preferred shares due to the oversubscribed offering. The amendment is then filed in order to reclassify capitalized Series F preferred shares in the amount of $3,087,000 (3,087 Series F preferred shares) to a subscription receivable, reverse of $86,553 in gain from the elimination of debt in the exchange of debt for Series F preferred shares, and to reverse $2,573 in accrued dividends for unissued series F preferred shares. In order to account for the oversubscribed series F preferred shares, the Company was required to issue a new series of preferred shares named series F-2. The series F-2 preferred shares have the same terms as provided by the series F preferred shares. No other changes to the Form 10-Q are included in this Amendment No. 1 other than as described above. This Amendment No. 1 does not modify or update any financial or other disclosures presented in the Form 10-Q other than as noted above, and does not reflect events occurring after the filing of the Form 10-Q. Accordingly, this Amendment No. 1 should be read in conjunction with the Form 10-Q, which provides information as of the date thereof. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto.
 
 
 
 
PART I - FINANCIAL INFORMATION: ITEM 1.  FINANCIAL STATEMENTS
 
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS (unaudited, in thousands)
 
ASSETS
 
March 31,
2021
 
 
December 31,
2020
 
CURRENT ASSETS:
 
 
 
 
 
 
    Cash and cash equivalents
 $1,247 
 $182 
    Accounts receivable, net of allowance for doubtful accounts of $126 at March 31, 2021 and December 31, 2020
  24 
  24 
    Inventory, net of reserves of $758 at March 31, 2021 and December 31, 2020
  606 
  605 
    Other current assets
  39 
  85 
                    Total current assets
  1,916 
  896 
NONCURRENT ASSETS:
    
    
    Property and equipment, net
  2 
  1 
    Lease asset-right, net of amortization
  426 
  453 
    Other assets
  18 
  - 
                    Total noncurrent assets
  446 
  454 
                    TOTAL ASSETS
  2,362 
  1,350 
 
    
    
LIABILITIES AND STOCKHOLDERS’ DEFICIT
    
    
CURRENT LIABILITIES:
    
    
    Current portion of long-term debt
  45 
  28 
    Notes payable in default, related parties
  - 
  1 
    Notes payable in default
  296 
  328 
    Short-term notes payable
  11 
  45 
    Short-term notes payable, related parties, past due
  74 
  51 
    Convertible notes in default
  110 
  - 
    Convertible notes payable, past due
  90 
  1,930 
    Short-term convertible notes payable
  915 
  951 
    Accounts payable
  2,427 
  2,419 
    Accounts payable, related parties
  137 
  116 
    Accrued liabilities
  4,895 
  2,995 
    Mandatorily redeemable Series G convertible preferred stock
  125 
  - 
    Current portion of lease liability
  42 
  56 
    Deferred revenue
  62 
  42 
                   Total current liabilities
  9,229 
  8,962 
LONG-TERM LIABILITIES:
    
    
    Warrants, at fair value
  - 
  2,203 
    Lease liability
  376 
  392 
    Derivative liability
  113 
  25 
    Long-term debt
  6 
  23 
    Long-term debt-related parties
  573 
  600 
                    Total long-term liabilities
  1,068 
  3,243 
                    TOTAL LIABILITIES
  10,297 
  12,205 
 
    
    
COMMITMENTS & CONTINGENCIES (Note 7)
    
    
 
 
 
  
STOCKHOLDERS’ DEFICIT:
 
 
 
 
 
 
Series C convertible preferred stock, $.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of March 31, 2021 and December 31, 2020. (Liquidation preference of $286 at March 31, 2021 and December 31, 2020).
  105 
  105 
Series C1 convertible preferred stock, $.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of March 31, 2021 and December 31, 2020. (Liquidation preference of $1,049 at March 31, 2021 and December 31, 2020).
  170 
  170 
Series C2 convertible preferred stock, $.001 par value; 5,000 shares authorized, 3.3 shares issued and outstanding as of March 31, 2021 and December 31, 2020. (Liquidation preference of $3,263 at March 31, 2021 and December 31, 2020).
  531 
  531 
Series D convertible preferred stock, $.001 par value; 6.0 shares authorized, 0.8 shares issued and outstanding as of March 31, 2021 and December 31, 2020. (Liquidation preference of $763 at March 31, 2021 and December 31, 2020).
  276 
  276 
Series E convertible preferred stock, $.001 par value; 5.0 shares authorized, 1.7 shares issued and outstanding as of March 31, 2021 and December 31, 2020. (Liquidation preference of $1,736 at March 31, 2021 and December 31, 2020).
  1,639 
  1,639 
Series F convertible preferred stock, $.001 par value; 1.5 shares authorized, 1.4 and nil shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. (Liquidation preference of $1,421 and nil at March 31, 2021 and December 31, 2020), respectively.
  1,195 
  - 
Series G convertible preferred stock, $.001 par value; 1,000 shares authorized, 153 and nil shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. (Liquidation preference of $153 and nil at March 31, 2021 and December 31, 2020), respectively.
  - 
  - 
Common stock, $.001 par value; 3,000,000 shares authorized, 13,180 and 13,138 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively
  3,403 
  3,403 
   Additional paid-in capital
  125,489 
  123,109 
   Treasury stock, at cost
  (132)
  (132)
   Accumulated deficit
  (140,611)
  (139,956)
                   TOTAL STOCKHOLDERS’ DEFICIT
  (7,935)
  (10,855)
  TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
  2,362 
  1,350 
 
The accompanying notes are an integral part of these consolidated statements. 
 
 
 
 
GUIDED THERAPEUTICS INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands)
 
 
 
FOR THE THREE MONTHS
ENDED MARCH 31,
 
 
 
 2021
 
 
 2020
 
REVENUE:
 
 
 
 
 
 
          Sales – devices and disposables, net
 $- 
 $- 
          Cost of goods sold
  - 
  - 
                                 Gross profit
  - 
  - 
 
    
    
OPERATING EXPENSES:
    
    
         Research and development
  16 
  24 
         Sales and marketing
  36 
  34 
         General and administrative
  770 
  184 
                                 Total operating expenses
  822 
  242 
 
    
    
                                 Operating loss
  (822)
  (242)
 
    
    
OTHER INCOME (EXPENSE):
    
    
         Other income
  - 
  1 
         Interest expense
  (141)
  (287)
         Change in fair value of derivative liability
  (88)
  - 
         Gain from extinguishment of debt
  - 
  28 
         Change in fair value of warrants
  448 
  3,228 
                                 Total other income
  219 
  2,970 
 
    
    
(LOSS) INCOME BEFORE INCOME TAXES
  (603)
  2,728 
 
    
    
PROVISION FOR INCOME TAXES
  - 
  - 
 
    
    
NET (LOSS) INCOME
  (603)
  2,728 
 
PREFERRED STOCK DIVIDENDS
  (52)
  (12)
 
    
    
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS
 $(655)
 $2,716 
 
    
    
NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO
COMMON STOCKHOLDERS
    
    
      BASIC
 $(0.050)
 $0.542 
      DILUTED
 $(0.050)
 $0.041 
 
    
    
WEIGHTED AVERAGE SHARES OUTSTANDING
    
    
      BASIC
  13,172 
  5,013 
      DILUTED
  13,172 
  65,620 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 
 
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2021 and 2020 (In Thousands)
 
 
 
Preferred Stock
Series C
 
 
Preferred Stock
Series C1
 
 
Preferred Stock
Series C2
 
 
Preferred Stock
Series D
 
 
Preferred Stock
Series E
 
 
Preferred Stock
Series F
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 Shares
 
 
 Amount
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
BALANCE, December 31, 2019
  - 
 $105 
  1 
 $170 
  3 
 $531 
  - 
 $- 
  - 
 $- 
  - 
 $- 
Issuance of preferred stock in financing
  - 
  - 
  - 
  - 
  - 
  - 
  1 
  268 
  - 
  - 
  - 
  - 
Conversion of debt into common stock
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of common stock in financing
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of warrants in financing
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of common stock for manufacturing agreements
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Accrued preferred dividends
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Net income
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
BALANCE, March 31, 2020
  - 
 $105 
  1 
 $170 
  3 
 $531 
  1 
 $268 
  - 
 $- 
  - 
 $- 
BALANCE, December 31, 2020
  - 
 $105 
  1 
 $170 
  3 
 $531 
  1 
 $276 
  2 
 $1,639 
  - 
 $- 
Series D preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Series E preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Series F preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  1 
  1,195 
Issuance of warrants to finders
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Series G preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of common stock for payment of Series D preferred dividends
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of warrants to consultants
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Conversion of warrants from liability to equity
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Stock-based compensation
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Accrued preferred dividends
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
BALANCE, March 31, 2021
  - 
 $105 
  1 
 $170 
  3 
 $531 
  1 
 $276 
  2 
 $1,639 
  1 
 $1.195 
 
The accompanying notes are an integral part of these consolidated statements.
 
 
 
 
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2021 and 2020 (In Thousands)
 
 
 
  Preferred Stock
Series G
 
 
 
Common Stock
 
 
Additional
Paid-In
 
 
 
Treasury
 
 
 
Accumulated
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Stock
 
 
Deficit
 
 
TOTAL
 
BALANCE, December 31, 2019
  - 
  - 
  3,319 
 $3,394 
 $118,552 
 $(132)
 $(139,555)
 $(16,935)
Issuance of preferred stock in financing
  - 
  - 
  - 
  - 
  286 
  - 
  - 
  554 
Conversion of debt into common stock
  - 
  - 
  6,957 
  7 
  2,068 
  - 
  - 
  2,075 
Issuance of common stock in financing
  - 
  - 
  1,476 
  1 
  177 
  - 
  - 
  178 
Issuance of warrants in financing
  - 
  - 
  - 
  - 
  67 
  - 
  - 
  67 
Issuance of common stock for manufacturing agreements
  - 
  - 
  13 
  - 
  - 
  - 
  - 
  - 
Accrued preferred dividends
  - 
  - 
  - 
  - 
  - 
  - 
  (12)
  (12)
Net income
  - 
  - 
  - 
  - 
  - 
  - 
  2,728 
  2,728 
BALANCE, March 31, 2020
  - 
 $- 
  11,765 
 $3,402 
 $121,150 
 $(132)
 $(136,839)
 $(11,345)
 
    
    
    
    
    
    
    
    
BALANCE, December 31, 2020
  - 
 $- 
  13,138 
 $3,403 
 $123,109 
 $(132)
 $(139,956)
 $(10,855)
Series D preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Series E preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Series F preferred offering
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  1,195 
Issuance of warrants to finders
  - 
  - 
  - 
  - 
  151 
  - 
  - 
  151 
Series G preferred offering
  153 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of common stock for payment of Series D preferred dividends
  - 
  - 
  42 
  - 
  14 
  - 
  - 
  14 
Issuance of warrants to consultants
  - 
  - 
  - 
  - 
  398 
  - 
  - 
  398 
Conversion of warrants from liability to equity
  - 
  - 
  - 
  - 
  1,755 
  - 
  - 
  1,755 
Stock-based compensation
  - 
  - 
  - 
  - 
  62 
  - 
  - 
  62 
Accrued preferred dividends
  - 
  - 
  - 
  - 
  - 
  - 
  (52)
  (52)
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  (603)
  (603)
BALANCE, March 31, 2021
  153 
 $- 
  13,180 
 $3,403 
 $125,489 
 $(132)
 $(140,611)
 $(7,935)
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 
 
GUIDED THERAPEUTICS INC. AND SUBSIDIARY  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
(unaudited, in thousands)  
 
 
 
FOR THE THREE MONTHS ENDED MARCH 31,  
 
 
 
2021
 
 
 2020  
 
CASH FLOWS FROM OPERATING ACTIVITIES:
 
   
 
 
     
 
     Net (loss) income
 $(603)
 $2,728 
     Adjustments to reconcile net (loss) income to net cash used in operating activities:
    
    
           Amortization of debt issuance costs and discounts
  64 
  94 
           Amortization of beneficial conversion feature
  8 
  19 
           Stock-based compensation
  62 
  - 
           Change in fair value of warrants
  (448)
  (3,228)
           Warrants issued for consulting services
  398 
  - 
           Gain from extinguishment of debt
  - 
  (28)
           Change in fair value of derivative
  88 
  - 
    Changes in operating assets and liabilities:
    
    
           Accounts receivable
  - 
  (11)
           Inventory
  (1)
  (9)
           Other current assets
  46 
  34 
           Other assets
  (18)
  - 
           Accounts payable
  29 
  (67)
           Deferred revenue
  20 
  - 
           Accrued liabilities
  658 
  (62)
                         Total adjustments
  906 
  (3,258)
 
    
    
                         Net cash provided (used) in operating activities
  303 
  (530)
 
    
    
CASH FLOWS FROM INVESTING ACTIVITIES:
    
    
      Additions to fixed assets
  (1)
  - 
                        Net cash used in investing activities
  (1)
  - 
 
    
    
CASH FLOWS FROM FINANCING ACTIVITIES:
    
    
      Proceeds from Series F offering, net of costs
  1,195 
  - 
      Proceeds from Series G offering, net of costs
  125 
  - 
      Payments made on notes payable
  (557)
  (451)
      Proceeds from the issuance of common stock
  - 
  103 
                        Net cash provided (used in) by financing activities
  763 
  (348)
 
    
    
NET CHANGE IN CASH AND CASH EQUIVALENTS
  1,065 
  (878)
CASH AND CASH EQUIVALENTS, beginning of year
  182 
  899 
CASH AND CASH EQUIVALENTS, end of period
 $1,247 
 $21 
SUPPLEMENTAL SCHEDULE OF:
    
    
Cash paid for:
    
    
     Interest
 $405 
 $165 
NONCASH INVESTING AND FINANCING ACTIVITIES:
    
    
  Issuance of common stock as debt repayment
 $- 
 $1,902 
  Issuance of warrants to finders in connection with Series F preferred stock
 $151 
 $- 
  Issuance of common stock for accrued interest of debt repaid
 $- 
 $162 
  Dividends on preferred stock
 $52 
 $12 
  Subscription receivable
 $3,087 
 $635 
  Settlement of dividends through common stock issuance
 $14 
 $- 
  Warrants exchanged for fixed price warrants
 $1,755 
 $67 
  Other receivable
 $- 
 $100 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 
 
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
  
1.
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION
 
Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.
 
Basis of Presentation
 
All information and footnote disclosures included in the consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States.
 
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. In the opinion of management, all adjustments (consisting of normal recurring accruals and other items) considered necessary for a fair presentation have been included.
 
The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2021, it had an accumulated deficit of approximately $140.6 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.
 
Going Concern
 
The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
 
At March 31, 2021, the Company had a negative working capital of approximately $7.3 million, accumulated deficit of $140.6 million, and incurred a net loss of $0.7 million for the three months then ended. Stockholders’ deficit totaled approximately $8.0 million at March 31, 2021, primarily due to recurring net losses from operations.
 
During the first quarter of 2021 the Company did raise $2.3 million as part of the Series F and G preferred stock capital raise. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised during 2021, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.
 
The Company had warrants exercisable for approximately 28.0 million shares of its common stock outstanding at March 31, 2021, with exercise prices ranging between $0.15 and $0.75 per share. Exercises of in the money warrants would generate a total of approximately $7.3 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.
 
2.   SIGNIFICANT ACCOUNTING POLICIES
 
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.
 
 
 
 
Principles of Consolidation
 
The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary. All intercompany transactions are eliminated.
 
Accounting Standard Updates
 
In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740)”. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending other areas of Topic 740. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2020. We adopted this ASU on January 1, 2021 with no material impact on our consolidated financial statements.
 
In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company has early adopted ASU No. 2020-06 under a modified retrospective basis on January 1, 2021. The result of the early adoption would have been a change to retained earnings of $102,000 for the year ended December 31, 2020.
 
Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements.
 
A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
 
Cash Equivalents
 
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
 
Accounts Receivable
 
The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility, is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.
 
Concentrations of Credit Risk
 
The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
 
 
 
 
Inventory Valuation
 
All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. At March 31, 2021 and December 31, 2020, our inventories were as follows (in thousands):
 
 
 
March 31,
 
 
December 31,
 
 
 
2021
 
 
2020
 
Raw materials
 $1,277 
 $1,276 
Work in process
  80 
  80 
Finished goods
  7 
  7 
Inventory reserve
  (758)
  (758)
       Total
 $606 
 $605 
 
    
    
The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
 
Property and Equipment
 
Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at March 31, 2021 and December 31, 2020 (in thousands):
 
 
 
March 31,
 
 
December 31,
 
 
 
2021
 
 
2020
 
Equipment
 $1,043 
 $1,042 
Software
  652 
  652 
Furniture and fixtures
  41 
  41 
Leasehold improvement
  12 
  12 
 
  1,748 
  1,747 
Less accumulated depreciation and amortization
  (1,746)
  (1,746)
            Total
 $2 
 $1 
 
    
    
 
During the three months ended March 31, 2021 and year ended December 31, 2020, the Company disposed of approximately nil and $647,000 of property and equipment that was fully depreciated, respectively.
 
Debt Issuance Costs
 
Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
 
Patent Costs (Principally Legal Fees)
 
Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $3,000 and $4,000 for the quarter ended March 31, 2021 and 2020, respectively.
 
 
 
 
Leases
 
With the implementation of ASU 2016-02, “Leases (Topic 842)”, the Company recorded a lease-right-of-use asset and a lease liability. The Company adopted the standard on January 1, 2019. The implementation required the analysis of certain criteria in determining its treatment. The Company determined that its corporate office lease met those criteria. The Company implemented the guidance using the alternative transition method. Under this alternative, the effective date would be the date of initial application. See Note 7: Commitments and Contingencies.
 
Accrued Liabilities
 
Accrued liabilities are summarized as follows (in thousands):
 
 
 
March 31,
2021
 
 
December 31,
 2020
 
Compensation
 $888 
 $1,094 
Professional fees
  41 
  83 
Subscription receivable
  3,380 
  - 
Interest
  256 
  1,517 
Vacation
  43 
  34 
Preferred dividends
  240 
  202 
Other accrued expenses
  47 
  65 
            Total
 $4,895 
 $2,995 
 
Subscription receivables
 
Cash received from investors for common stock shares that has not completed processing is recorded as a liability to subscription receivables. As of March 31, 2021, and December 31, 2020 the Company had an outstanding amount due of $3,380,000 and nil, respectively. The balance was primarily due to series F preferred stock that was oversubscribed by cash investment and exchanged debt in the amount of $3,087,479. The Company issued 3,087 series F-2 preferred stock during the second quarter of 2021 for the $3,087,479 subscription receivable, excluding the fair value of warrants issued in conjunction with the series F-2 preferred stock and any costs to raise capital. The subscription receivable was also reduced by $56,670 for finder’s fees.
 
Revenue Recognition
 
The Company follows, ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.
 
The Company did not have revenues for the three months ended March 31, 2021 and 2020.
 
 
 
 
Significant Distributors
 
Accounts receivable outstanding was $24,000, the outstanding amount was netted against a $126,000 allowance, which was from one distributor as of March 31, 2021 and December 31, 2020.
 
Deferred revenue
 
The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of March 31, 2021, and December 31, 2020, the Company had $62,000 and $42,000 in deferred revenue, respectively.
 
Research and Development
 
Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
 
Income Taxes
 
The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized.
 
The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2020, the Company has approximately $61.6 million of net operating losses carryforward available to next year. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses.
 
The current corporate tax rate in the U.S. is 21%.
 
Uncertain Tax Positions
 
The Company assesses each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2020 and, 2019, there were no uncertain tax positions.
 
The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia.
 
Warrants
 
The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
 
Stock Based Compensation
 
The Company records compensation expense related to options granted to employees and non-employees based on the fair value of the award. Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all stock based payments granted or modified subsequently based on fair value estimates.
 
 
 
 
On July 14, 2020, the Company granted stock options to employees and consultants. The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant.
 
Stock options granted have a 10-year life and expire 90 days after employment or upon termination of consulting agreement. Vesting schedule varies per grantee. Generally stock options granted vest as follows: 25% vest immediately, and the remaining stock options vest over 33 months, beginning three months after grant.
 
For the three months ended March 31, 2021 and 2020 share-based compensation for options attributable to employees, non-employees, officers and Board members were approximately $62,000 and $5,000, respectively. These amounts have been included in the Company’s statements of operations under general and administrative expense. Compensation costs for stock options which vest over time are recognized over the vesting period. As of March 31, 2021, and 2020 the Company had approximately $509,000 and nil of unrecognized compensation costs related to granted stock options that will be recognized, respectively.
 
Beneficial Conversion Features of Convertible Securities
 
The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as a derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.
 
Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence.
 
The Company also adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt.
 
Derivatives
 
The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
 
Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.
 
4.  STOCKHOLDERS’ DEFICIT
 Common Stock
 
The Company has authorized 3,000,000,000 shares of common stock with $0.001 par value, of which 13,180,417 were issued and outstanding as of March 31, 2021. As of December 31, 2020, there were 3,000,000,000 authorized shares of common stock, of which 13,138,282 were issued and outstanding.
 
For the three months ended March 31, 2021, the Company issued 42,135 shares of common stock as listed below:
 
Shares issued for payments of Series D dividends
  42,135 
Issued during the three months ended March 31, 2021
  42,135 
 
 
 
 
Summary table of common stock share transactions:
 
Balance at December 31, 2020
  13,138,282 
Issued in 2021
  42,135 
Balance at March 31, 2021
  13,180,417 
 
Investments
 
During 2021, the Company received equity investments in the amount of $2,099,000 and incurred fees due on these investments of $131,000. These investors received a total of 1,421 Series F preferred stock (if the Investor elects to convert their Series F preferred stock, each Series F preferred stock shares converts into 4,000 shares of the Company’s common stock shares) and $678,000 was recorded as subscription receivable for the oversubscribed amounts received for the three months ended of March 31, 2021. The investors for the oversubscribed amount received Series F-2 preferred stock shares during the second quarter of 2021.
 
During 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $132,000, net to the Company is $125,000, for 153,000 shares of Series G preferred stock.
 
During 2020, the Company received equity investments in the amount of $1,735,500 and incurred fees due on these investments of $96,985. These investors received a total of 1,736 Series E preferred stock (if the Investor elects to convert their Series E preferred stock, each Series E preferred stock shares converts into 4,000 shares of the Company’s common stock shares).
 
During January and April 2020, the Company received equity investments in the amount of $128,000. These investors received a total of 256,000 common stock shares and 256,000 warrants issued to purchase common stock shares at a strike price of $0.25, 256,000 warrants to purchase common stock shares at a strike price of $0.75 and 128 Series D preferred stock (if the Investor elects to convert their Series D preferred stock, each Series D preferred stock shares converts into 3,000 shares of the Company’s common stock shares). Of the amount invested $38,000 was from related parties.
 
Debt Exchanges - 2021
 
On January 8, 2021, the Company made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On March 31, 2021, the Company recorded this exchange as a subscription receivable and it will issue 2,236 series F-2 preferred stock shares in accordance with the terms of the agreement (see NOTE 10: CONVERTIBLE DEBT) during the second quarter of 2021.
 
On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel, The Company recorded this exchange as a subscription receivable and it will issue 100 and 85 series F-2 preferred stock shares, respectively in accordance with the terms of the agreement during the second quarter of 2021.
 
On March 10, 2021, the Company exchanged $88,000 in accrued consulting fees for Mr. Blumberg. The Company recorded this exchange as a subscription receivable and it will issue 88 series F-2 preferred stock shares in accordance with the terms of the agreement during the second quarter of 2021.
 
On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company recorded this exchange as a subscription receivable and it will issue 50 series F-2 preferred stock shares in accordance with the terms of the agreement during the second quarter of 2021 (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler remains on the Company health insurance plan. The note will accrue interest at the rate of 6% (18% in the event of default) on March 22, 2022 and be payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022.
 
Debt Exchanges - 2020
 
On January 8, 2020, the Company exchanged $2,064,366 in debt for several equity instruments (noted below) that were determined to have a total fair value of $2,065,548, resulting in a loss on extinguishment of debt of $1,183 which is recorded in other income (expense) on the accompanying consolidated statements of operations. The Company also issued 6,957,013 warrants to purchase common stock shares; with exercise prices of $0.25, $0.75 and $0.20. In addition, one of the investors forgave approximately $29,000 of debt, which was recorded as a gain for extinguishment of debt.
 
On June 3, 2020, the Company exchanged $328,422 in debt from Auctus, (summarized in footnote 10: Convertible Notes), for 500,000 common stock shares and 700,000 warrants to purchase common stock shares. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for the Company’s stock) and of the warrants to purchase common stock shares was $196,818 (based on a $0.281 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $118,396 ($446,818 fair value less the $328,422 of exchanged debt).
 
 
 
 
On June 30, 2020, the Company exchanged $125,000 in debt (during June 2020, $125,000 in payables had been converted into short-term debt) from Mr. James Clavijo, for 500,000 common stock shares and 250,000 warrants to purchase common stock shares. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for the Company’s stock) and of the warrants to purchase common stock shares was $99,963 (based on a $0.40 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $224,963 ($349,963 fair value less the $125,000 of exchanged debt). After the exchange transaction a balance was due to Mr. Clavijo of $10,213 which was paid.
 
On July 9, 2020, the Company entered into an exchange agreement with Mr. Bill Wells (one of its former employees) for an outstanding debt to him of $220,000. In lieu of agreeing to dismiss approximately half of what is owed by the Company, Mr. Wells will receive the following: (i) cash payments of $20,000 within 60 days of the signing of the agreement; cash payments over time in the amount of $90,000 in the form of an unsecured note with the Company to be executed within 30 days of a new financing(s) totaling at least $3.0 million. The note shall bear interest of 6.0% and mature over 18 months; (ii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (iii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2020, the Company made a payment of $20,000; this payment allowed the Company to reduce $40,000 in debt, with the corresponding $20,000 difference recorded as a gain.
 
The following table summarizes the 2020 debt exchanges:
 
 
 
Total Debt and Accrued Interest
 
 
Total Debt  
 
 
Total
Accrued
Interest
 
 
Common
Stock
Shares
 
 
Warrants
(Exercise $0.25)
 
 
Warrants
(Exercise $0.75)
 
 
Warrants
(Exercise $0.20)
 
 
Warrants
(Exercise $0.15)
 
 
Warrants
(Exercise $0.50)
 
Aquarius
 $145,544 
 $107,500 
 $38044 
  291,088 
  145,544 
  145,544 
  - 
  - 
  - 
K2 Medical (Shenghuo)3
  803,653 
  771,927 
  31,726 
  1,905,270 
  704,334 
  704,334 
  496,602 
  - 
  - 
Mr. Blumberg
  305,320 
  292,290 
  13,030 
  1,167,630 
  119,656 
  119,656 
  928,318 
  - 
  - 
Mr. Case
  179,291 
  150,000 
  29,291 
  896,456 
  - 
  - 
  896,456 
  - 
  - 
Mr. Grimm
  51,050 
  50,000 
  1,050 
  255,548 
  - 
  - 
  255,548 
  - 
  - 
Mr. Gould
  111,227 
  100,000 
  11,227 
  556,136 
  - 
  - 
  556,136 
  - 
  - 
Mr. Mamula
  15,577 
  15,000 
  577 
  77,885 
  - 
  - 
  77,885 
  - 
  - 
Dr. Imhoff2
  400,417 
  363,480 
  36,937 
  1,699,255 
  100,944 
  100,944 
  1,497,367 
  - 
  - 
Ms. Rosenstock1
  50,000 
  50,000 
  - 
  100,000 
  50,000 
  50,000 
  - 
  - 
  - 
Mr. James2
  2,286 
  2,000 
  286 
  7,745 
  1,227 
  1,227 
  5,291 
  - 
  - 
Auctus
  328,422 
  249,119 
  79,303 
  500,000 
  - 
  - 
  - 
  700,000 
  - 
Mr. Clavijo
  125,000 
  125,000 
  - 
  500,000 
  - 
  - 
  - 
  - 
  500,000 
Mr. Wells4
  220,000 
  220,000 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
 
 $2,737,787 
 $2,496,316 
  241471 
  7,957,013 
  1,121,705 
  1,121,705 
  4,713,603 
  700,000 
  500,000 
 
1 Ms. Rosenstock also forgave $28,986 in debt to the Company.
2 Mr. Imhoff and Mr. James are members of the board of directors and therefore related parties.
3 The Company’s COO and director, Mark Faupel, is a shareholder of Shenghuo, and a former director, Richard Blumberg, is a managing member of Shenghuo.
4 Mr. Wells will also receive 66,000 common share stock options; the details of which are explained above.
 
Preferred Stock
 
The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions.
 
Series C Convertible Preferred Stock
 
The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At March 31, 2021 and December 31, 2020, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 572,000 common stock shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt.
 
 
 
 
Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. In addition, upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At March 31, 2021 and December 31, 2020, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. At March 31, 2021 and December 31, 2020, the exercise price per share was $512,000.
 
Series C1 Convertible Preferred Stock
 
The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,050 shares were issued and outstanding at March 31, 2021 and December 31, 2020. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At March 31, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock.
Between April 27, 2016 and May 3, 2016, the Company entered into various agreements with certain holders of Series C preferred stock, including directors John Imhoff and Mark Faupel, pursuant to which those holders separately agreed to exchange each share of Series C preferred stock held for 2.25 shares of the Company’s newly created Series C1 Preferred Stock and 12 (9,600 pre-split) shares of the Company’s common stock (the “Series C Exchanges”). In connection with the Series C Exchanges, each holder also agreed to roll over the $1,000 stated value per share of the holder’s shares of Series C1 Preferred Stock into the next qualifying financing undertaken by the Company on a dollar-for-dollar basis and, except in the event of an additional $50,000 cash investment in the Company by the holder, to execute a customary “lockup” agreement in connection with the financing. In total, for 1,916 shares of Series C preferred stock surrendered, the Company issued 4,312 shares of Series C1 Preferred Stock and 29 shares of common stock.
 
On August 31, 2018, 3,262.25 shares of Series C1 Preferred Stock were surrendered, and the Company issued 3,262.25 shares of Series C2 Preferred Stock.
At March 31, 2021 and December 31, 2020, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 2,098,500 common stock shares.
 
The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt.
 
Series C2 Convertible Preferred Stock
 
On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At March 31, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 6,524,500 common stock shares.
 
The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing.
Series D Convertible Preferred Stock
 
The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 763 of which remain outstanding. On January 8, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000 common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable $0.75. Each Series D Preferred Stock is convertible into 3,000 common stock shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of March 31, 2021, none of the 763 Series E Preferred Shares have been converted to secured debt.
 
 
 
 
Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.
 
On January 8, 2020, the Company also entered into a Registration Rights Agreement (the “Series D Registration Rights Agreement “) with the Series D Investors pursuant to which the Company agreed to file with the SEC, a registration statement on a Form S-3 (or on other appropriate form if a Form S-3 is not available) covering the Common Stock issuable upon conversion of the Series D Warrants within 90 days of the date of the Registration Rights Agreement and cause such registration statement to be declared effective within 120 days of the date of the Registration Rights Agreement. All reasonable expenses related to such registration shall be borne by the Company.
 
During January 2021, the Company issued 42,135 common stock shares for the payment of Series D Preferred Stock dividends accrued. As of March 31, 2021, the Company had accrued dividends of $14,306.
 
Series E Convertible Preferred Stock
 
The Board designated 6,000 shares of preferred stock as Series E Preferred Stock, 1,736 of which remain outstanding. During year ended December 31, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series E Investors”). In total, for $1,736,000 the Company issued 1,736 shares of Series E Preferred Stock. Each Series E Preferred Stock is convertible into 4,000 common stock shares. The Series E Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series E Preferred Stock is $1,736. The Company incurred fees due on these investments of $91,895.
Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of March 31, 2021, the Company had not issued shares as payment of Series E Preferred Stock dividends. As of March 31, 2021, the Company had accrued dividends of $101,957.
 
Series F Convertible Preferred Stock
 
The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,421 of which remain outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,421,000 the Company issued 1,421 shares of Series F Preferred Stock. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.
 
Powerup (Series G Convertible Preferred Stock)
 
During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred.
 
During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred.
 
Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability.
 
 
 
 
Warrants
 
The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the three months ended March 31, 2021:
 
 
 
Warrants
(Underlying Shares)
 
Outstanding, January 1, 2021
  28,324,275 
Issuances
  1,446,000 
Canceled / Expired
  (1,729,262)
Exercised
  - 
Outstanding, March 31, 2021
  28,041,013 
 
The Company had the following shares reserved for the warrants as of March 31, 2021:
 
 
Warrants
(Underlying Shares)  
 
Exercise Price
Expiration Date
  7,185,000(1)
$0.20 per shareFebruary 12, 2023
  325,000(2)
$0.18 per shareApril 4, 2022
  215,000(3)
$0.25 per shareJuly 1, 2022
  100,000(4)
$0.25 per shareSeptember 1, 2022
  7,500,000(5)
$0.20 per shareDecember 17, 2024
  250,000(6)
$0.16 per shareMarch 31, 2025
  2,597,705(7)
$0.25 per shareDecember 30, 2022
  2,597,705(8)
$0.75 per shareDecember 30, 2022
  4,713,603(9)
$0.20 per shareDecember 30, 2022
  60,000(10)
$0.25 per shareApril 23, 2023
  50,000(11)
$0.25 per shareDecember 30, 2022
  50,000(12)
$0.75 per shareDecember 30, 2022
  700,000(13)
$0.15 per shareMay 21, 2023
  250,000(14)
$0.50 per shareJune 23, 2023
  1,000(15)
$0.50 per shareAugust 10, 2022
  1,250,000(16)
$0.25 per shareFebruary 22, 2023
  196,000(17)
$0.25 per shareMarch 3, 2024
  28,041,013 
  
 
(1)
Exchanged in January 2020 from amount issued as part of a February 2016 private placement with senior secured
debt holder
(2)Issued to investors for a loan in April 2019
(3)Issued to investors for a loan in July 2019
(4)Issued to investors for a loan in September 2019
(5)Issued to investors for a loan in December 2019
(6)Issued to investors for a loan in January 2020
(7)Issued to investors as part of Series D Preferred Stock Capital raise in December 2020
(8)Issued to investors as part of Series D Preferred Stock Capital raise in December 2020
(9)Issued to investors as part of Series D Preferred Stock Capital raise in December 2020
(10)Issued to a consultant for services in April 2020
(11)
(12)
(13)
(14)
(15)
(16)
Issued to an investor as part of Series D Preferred Stock Capital raise in April 2020
Issued to an investor as part of Series D Preferred Stock Capital raise in April 2020
Issued to an investor for a loan in May 2020
Issued to an investor in exchange of debt in June 2020
Issued to a consultant for services in August 2020
Issued to a consultant (director) in February 2021
(17)Issued to a consultant for Series F Preferred Stock Capital raise in March 2021 
 
 
 
 
Footnote (1) - On January 16, 2020, the Company entered into an exchange agreement with GPB. This exchange agreement canceled the existing outstanding warrants, which were subject to anti-dilution and ratchet provisions, to purchase 35,937,500 shares of common stock at an exercise price of $0.04 per share and resulted in the issuance of new warrants to purchase 7,185,000 share of common stock at a price of $0.20 per share. The new warrants have fixed exercise prices of $0.20. On January 8, 2021, the Company met the requirement by making the final payment of $750,000 as required by the exchange agreement with GPB, which canceled the previously issued warrants.
 
Warrant to purchase 70 shares of common stock were not recorded as their exercise price after considering reverse stock splits, were greater than $60,000 and deemed to be immaterial for disclosure
 
On January 6, 2020, the Company entered into a finder’s fee agreement. The finder will receive 5% cash and 5% warrants on all funds it raises including bridge loans. The three-year common stock share warrants will have an exercise price of $0.25. During 2019 and 2020, the finder helped the Company raise $300,000, therefore a fee of $31,650 was paid and 126,600 warrants will be issued.
 
10.  CONVERTIBLE DEBT
 
Senior Secured Promissory Note
 
As of March 31, 2021, all Senior Secured debt due to GPB had been exchanged for a subscription receivable, this subscription is for 2,236 Series F-2 preferred stock shares that will be issued in the second quarter of 2021, in accordance with the terms of the January 15, 2020 exchange agreement. In addition, the common stock purchase warrant exercise price had been adjusted to $0.20 and the number of common stock shares exchangeable for was 7,185,000. The exchange agreement was subject to the Company meeting repayment conditions, which the Company did. Those conditions involved in part the repayment of $450,000, $100,000 and $950,000 for the completion of each Auctus financing tranche. Further on September 2, 2020, the Company made a payment of $50,000, which provided the Company a four-month forbearance as well as paying and additional $150,000 to reduce the balance outstanding at that time. On January 8, 2021, the Company made the final payment of $750,000 as required by this exchange agreement with GPB.
 
On February 12, 2016, the Company entered into a securities purchase agreement with GPB Debt Holdings II LLC (“GPB”) for the issuance of a $1,437,500 senior secured convertible note for an aggregate purchase price of $1,029,000 (representing an original issue discount of $287,500 and debt issuance costs of $121,000). On May 28, 2016, the balance of the note was increased by $87,500 for a total principal balance of $1,525,000. On December 7, 2016, the Company entered into an exchange agreement with GPB and as a result the principal balance increased by a transfer $312,500 (see – “Senior Secured Promissory Note”) for a total principal balance of $1,837,500.
 
In connection with the transaction, on February 12, 2016, the Company and GPB entered into a four-year consulting agreement, pursuant to which the investor will provide management consulting services to the Company in exchange for a royalty payment, payable quarterly, equal to 3.85% of the Company’s revenues from the sale of products. As of March 31, 2021 and December 31, 2020, and 2019, GPB had earned approximately $35,000 in royalties that are unpaid. Based on the exchange agreement GPB will no longer earn royalties.
 
As of December 31, 2020, the balance due on the convertible debt was $1,709,414, consisting of principal of $1,362,384 and a prepayment penalty of $347,030. Interest accrued on the note total $1,233,637 at December 31, 2020, and is included in accrued expenses on the accompanying consolidated balance sheet.
 
The Company used a placement agent in connection with the transaction. For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction, at an exercise price equal to, and terms otherwise identical to, the warrant issued to the investor. Finally, the Company agreed to reimburse the placement agent for its reasonable out-of-pocket expenses. The warrants issued to that placement agent had expired during the three months ended March 31, 2021.
 
Other Convertible Debt
 
GHS
 
Effective May 19, 2017, the Company entered into a securities purchase agreement with GHS for the purchase of a $66,000 convertible promissory note for the purchase of $60,000 in net proceeds (representing a 10% original issue discount of $6,000). The accrued interest rate of 8% per year until it matured in December 31, 2017. Beginning February 2018, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price during the 25 trading days prior to conversion. Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. GHS converted $12,700 of principal and accrued interest during the year ended December 31, 2019. On December 16, 2020, the Company paid $25,000 on the note balance. At March 31, 2021 the note was paid in full. On December 31, 2020, the balance due on this note was $63,520 including a default penalty of $37,926. Interest accrued on the note totaled $17,816, at December 31, 2020 and is included in accrued expenses on the accompanying consolidated balance sheet.
 
Effective May 17, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a convertible promissory note with a principal of $9,250 for a purchase price of $7,500 (representing an original issue discount of $750 and debt issuance costs of $1,000). The note accrued interest at a rate of 8% per year until its matured June 17, 2019. Beginning February 2018, the note is convertible, in whole or in part, at the holder's option, into shares of the Company's stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. As of March 31, 2021, the note was paid in full. At December 31, 2020, the balance due on this note was $14,187, including a default penalty of $4,937. Interest accrued on the note totaled $5,006 at December 31, 2020, and is included in accrued expenses on the accompanying consolidated balance sheet.
 
Effective June 22, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a $68,000 convertible promissory note for a purchase price of $60,000 (representing an original issue discount of $6,000 and debt issuance costs of $2,000). At issuance, the Company recorded a $29,143 beneficial conversion feature, which was fully amortized at December 31, 2019. The accrued interest at a rate of 10% per year until it matured on June 22, 2019. Beginning May 2019, the note is convertible, in whole or in part, at the holder's option, into shares of the Company's stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. At March 31, 2021 and December 31, 2020, the balance due on this note was $90,348 and $103,285, respectively and includes a default penalty of $35,285. Interest accrued on the note totals $36,906 and $39,644 at March 31, 2021 and December 31, 2020, respectively, and is included in accrued expenses on the accompanying consolidated balance sheet.
 
 
 
 
Auctus
 
On May 22, 2020, the Company entered into an exchange agreement with Auctus. Based on this agreement the Company exchanged three outstanding notes, in the amounts of $150,000, $89,250, and $65,000 for a total amount $328,422 of debt outstanding, as well as any accrued interest and default penalty, for: $160,000 in cash payments (payable in monthly payments of $20,000), converted a portion of the notes pursuant to original terms of the notes into 500,000 restricted common stock shares (shares were issued on June 3, 2020); and 700,000 warrants issued to purchase common stock shares at a strike price of $0.15. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for the Company’s stock) and of the warrants to purchase common stock shares was $196,818 (based on a $0.281 black scholes fair valuation). During the year ended December 31, 2020, the Company paid $100,000 to reduce the outstanding balance. As of March 31, 2021, the balance was paid in full. At December 31, 2020, a balance of $40,000 remained to be paid for these exchanged loans.
 
Auctus notes exchanged in the May 22, 2020 transaction
 
Effective March 20, 2018, the Company entered into a securities purchase with Auctus Fund, LLC ("Auctus") for the issuance of a $150,000 convertible promissory note and warrants exercisable for 4,262 shares of the Company's common stock. At issuance, the Company recorded a $97,685 beneficial conversion feature, which was fully amortized at December 31, 2018. The warrants are exercisable at any time, at an exercise price equal to $0.04 per share, subject to certain customary adjustments and price-protection provisions contained in the warrant. The warrants have a five-year term. The note accrued interest at a rate of 12% per year until it matured in December 2018. Beginning December 2018, the note is convertible, in whole or in part, at the holder's option, into shares of the Company's stock at a conversion price equal to 60% of the lowest trading price during the 20 trading days prior to conversion. Upon the occurrence of an event of default, the note will bear interest at a rate of 24% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. On May 22, 2020, the default penalty and outstanding interest was exchanged as described in the preceding paragraph. As of March 31, 2021, the note was paid in full. During the year ended December 31, 2020, the Company paid $100,000 to reduce the outstanding balance. As of December 31, 2020, a balance of $40,000 remained to be paid for these exchanged loans.
 
On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On March 31, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matures on January 26, 2021 and accrues interest at a rate of 12% per year. We may not prepay the note, in whole or in part. After the 90th calendar day after the issuance date, and ending on the later of maturity date and the date of payment of the default amount, Auctus may convert the note, at any time, in whole or in part, provided such conversion does not provide Auctus with more than 4.99% of the outstanding common share stock. The conversion may be made converted into shares of the our common stock, at a conversion price equal to the lesser of: (i) the lowest Trading Price during the twenty-five (25) trading day period on the last trading prior to the issue date and (ii) the variable conversion price (55% multiplied by the market price, market price means the lowest trading price for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. Trading price is the lowest trade price on the trading market as reported. The note includes customary events of default provisions and a default interest rate of 24% per year. As of March 31, 2021 and December 31, 2020, the note outstanding was $112,750, which consisted of unamortized balance of $8,424 of a beneficial conversion feature. In addition, as of March 31, 2021 and December 31, 2020, unamortized debt issuance costs of $2,550 and $5,100 and interest of $13,643 and $10,260 are included in accrued expenses on the accompanying consolidated balance sheet, respectively.
 
The following table summarizes the Convertible notes (including debt in default):
 
 
 
March 31, 2021
 
 
December 31, 2020
 
GPB
 $- 
 $- 
 $1,709 
 $1,709 
GHS
  - 
    
  64 
    
 
  - 
    
  14 
    
 
  90 
  90 
  103 
  181 
Auctus
  110 
  110 
  - 
  40 
Convertible notes, past due (including debt in default)
    
 $200 
    
 $1,930 
 
The convertible notes payable, past due was $200,000 and $1,930,000 at March 31, 2021 and December 31, 2020, respectively.
 
Troubled Debt Restructuring
 
During 2021, the Company restructured debt with GPB resulting in the exchange of $1,709,000 of convertible debt. This debt restructure met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of March 31, 2021, the troubled debt restructuring for Convertible Debt, would have decreased the net loss by $449,000 and causing the per share calculation to change from .04 to .07 net loss per share.
 
 
 
 
11.  LONG-TERM DEBT
 
Long-term Debt – Related Parties 
 
On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. The modification also included simple interest at a 6% rate, with the principal and accrued interest due in total at the date of maturity or September 4, 2021, the terms are currently being updated and an amended modification is expected to be completed.
 
During the quarter ended September 30, 2018, the Company entered into an exchange agreement dated July 14, 2018, Dr Faupel, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $661,000 for a $207,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $199,000 and a capital contribution of $235,000 during the year ended December 31, 2018. The resulting difference of $20,000 was recorded to accrued interest. In the July 20, 2018 exchange agreement, Dr, Cartwright, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,000 for a $319,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $840,000 and a capital contribution of $432,000 during the year ended December 31, 2018. The resulting difference of $30,000 was recorded to accrued interest and elimination of debt.
 
On February 19, 2021, the Company entered into a new promissory note replacing the original note from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6%.
 
On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel. The Company recorded this exchange as a subscription receivable and it will issue 100 and 85 series F-2 preferred stock shares, respectively in accordance with the terms of the agreement during the second quarter of 2021.
 
The table below summarizes the detail of the exchange agreement:
 
For Dr. Faupel:
 
Salary
 $134 
Bonus
  20 
Vacation
  95 
Interest on compensation
  67 
Loans to Company
  196 
Interest on loans
  149 
        Total outstanding prior to exchange
 $661 
 Amount forgiven
  (454)
 Total Interest accrued through December 31, 2020
  29 
        Balance outstanding at December 31, 2020
 $236 
        Exchange for Series F Preferred Stock
  (85)
        Interest accrued through March 31, 2021
  3 
        Balance outstanding at March 31, 2021
 $154 
  
For Dr. Cartwright:
 
Salary
 $337 
Bonus
  675 
Interest on compensation
  528 
Loans to Company
  196 
Interest on loans
  149 
        Total outstanding prior to exchange
 $1,621 
 Amount forgiven
  (1,302)
 Total Interest accrued through December 31, 2020
  45 
        Balance outstanding at December 31, 2020
 $364 
        Exchange for Series F Preferred Stock
  (100)
        Interest accrued through March 31, 2021
  5 
        Balance outstanding at March 31, 2021
 $269 
 
 
 
 
On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company recorded this exchange as a subscription receivable and it will issue 50 series F-2 preferred stock shares in accordance with the terms of the agreement during the second quarter of 2021 (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler remains on the Company health insurance plan. The note will accrue interest at the rate of 6% (18% in the event of default) on March 22, 2022 and be payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022.
 
Future debt obligations at March 31, 2021 for Long-term Debt – Related Parties are as follows (in thousands):
 
Year
 
 Amount
 
 2021  
 $- 
 2022  
  - 
 2023  
  456 
 2024  
  43 
 2025  
  43 
 Thereafter  
  31 
 Totals  
 $573 
 
 
Long-term debt
 
On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan bears interest at a rate of 1.00%, and matures in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. Lender will apply each payment first to pay interest accrued to the day Lender received the payment, then to bring principal current, and will apply any remaining balance to reduce principal. Payments must be made on the same day as the date of this Note in the months they are due. Lender shall adjust payments at least annually as needed to amortize principal over the remaining term of the Note. Under the provisions of the PPP, the loan amounts will be forgiven as long as: the loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over a 24 week period after the loan is made; and employee and compensation levels are maintained. In addition, payroll costs are capped at $100,000 on an annualized basis for each employee. Not more than 40% of the forgiven amount may be for non-payroll costs. As of March 31, 2021 and December 31, 2020, the outstanding balance was $50,604 and $50,477 including $420 and $293 in accrued interest, respectively. The Company was notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. The Company is planning on appealing the amount forgiven.
 
Troubled Debt Restructuring
 
The debt extinguished for Mr. Cartwright and Mr. Faupel meet the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. As of March 31, 2021, the troubled debt restructuring for Long-term Debt – Related Parties, would have decreased the net loss by $346,000 and causing the per share calculation to change from .04 to .07 net loss per share.
 
 
12.  INCOME (LOSS) PER COMMON SHARE
 
Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year.
 
Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series D, Series E and Series F convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares.
 
 
 
 
The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.
 
In thousands
 
March 31,
 
 
 
2021
 
 
2020
 
 
 
 
 
 
 
 
Net (loss) income
 $(655)
 $2,716 
 
Basic weighted average number of shares outstanding
  13,172 
  5,013 
 
Net (loss) income per share (basic)
 $(0.050)
 $0.542 
 
Diluted weighted average number of shares outstanding
  13,172 
  65,620 
 
Net (loss) income per share (diluted)
 $(0.050)
 $0.0415 
 
 
    
 
    
Dilutive equity instruments (number of equivalent units):
    
 
    
Stock options
  - 
  - 
 
Preferred stock
  9,998 
  - 
 
Convertible debt
  315 
  59,282 
 
Warrants
  17,400 
  1,325 
 
Total Dilutive instruments
  27,713 
  60,607 
 
 
For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt are anti-dilutive.
 
Troubled Debt Restructuring
 
As provided in the preceding footnotes, several transactions met the basic criteria for troubled debt, which are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. As of March 31, 2021, the troubled debt restructuring in total would have decreased the net loss by $972,000 and causing the per share calculation to change from .04 to .11 net loss per share.
 
13. SUBSEQUENT EVENTS
 
On April 29, 2021, the Company made a $25,000 payment to an investment banker to assist in financing efforts, which will be presented within prepaid expenses as of June 30, 2021. These costs will be charged against the gross proceeds of the offering when it occurs.
 
During May 2021, the Company entered into several securities purchase agreements for the issuance of 10.0% senior secured convertible debentures. Each debenture unit will represent a subscription price of $1,000 per debenture unit. The debentures are convertible into shares of common stock at a price of $0.50 for a period of thirty-six months from the closing date. In addition, the investors will receive one two-year warrant to purchase one common stock share at an exercise price of $0.80 per share. As of May 17, 2021, the Company had subscription agreements for 868 debentures and received a total of $868,000.
 
 
 
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Statements in this report which express "belief," "anticipation" or "expectation," as well as other statements which are not historical facts, are forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those that may be set forth under "Risk Factors" below and elsewhere in this report, as well as in our annual report on Form 10-K for the year ended December 31, 2020 and subsequently filed quarterly reports on Form 10-Q. Examples of these uncertainties and risks include, but are not limited to:
 
access to sufficient debt or equity capital to meet our operating and financial needs;
the extent of dilution of the holdings of our existing stockholders upon the issuance, conversion or exercise of securities issued as part of our capital raising efforts;
the extent to which certain debt holders may call the notes to be paid;
the effectiveness and ultimate market acceptance of our products and our ability to generate sufficient sales revenues to sustain our growth and strategy plans;
whether our products in development will prove safe, feasible and effective;
whether and when we or any potential strategic partners will obtain required regulatory approvals in the markets in which we plan to operate;
our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;
the lack of immediate alternate sources of supply for some critical components of our products;
our ability to establish and protect the proprietary information on which we base our products, including our patent and intellectual property position;
Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions in our operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites;
The future impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreak will not have a material adverse impact on our operations or future results or filings with regulatory health authorities. The extent of the impact, if any, we will depend on future developments, including actions taken to contain the coronavirus;
the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines;
the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products; and
other risks and uncertainties described from time to time in our reports filed with the SEC.
 
The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.
 
OVERVIEW
 
We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.
 
LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva improves patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.
 
We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.,” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our wholly owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”
 
Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants.
 
Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of March 31, 2021 we have an accumulated deficit of approximately $140.6 million. To date, we have engaged primarily in research and development efforts and the early stages of marketing our products. We do not have significant experience in manufacturing, marketing or selling our products. We may not be successful in growing sales for our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.
 
Our product revenues to date have been limited. In 2020, the majority of our revenues were from the sale of components of our LuViva devices and disposables. We expect that the majority of our revenue in 2021 will be derived from revenue from the sale of LuViva devices and disposables.
 
 
 
 
Current Demand for LuViva
 
Based on discussions with our distributors, we currently hold and expect to generate additional purchase orders for approximately $2.0 to $3.0 million in LuViva devices and disposables in 2021 and expect those purchase orders to result in actual sales of $1.0 to $2.0 million in 2021, representing what we view as current demand for our products. We cannot be assured that we will generate all or any of these additional purchase orders, or that existing orders will not be canceled by the distributors or that parts to build product will be available to meet demand, such that existing orders will result in actual sales. Because we have a short history of sales of our products, we cannot confidently predict future sales of our products beyond this time frame and cannot be assured of any particular amount of sales. Accordingly, we have not identified any particular trends with regard to sales of our products.
 
CRITICAL ACCOUNTING POLICIES
 
Our material accounting policies, which we believe are the most critical to investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. When we begin to generate revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.
 
Revenue Recognition: ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.
 
Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.
 
Valuation of Equity Instruments Granted to Employee, Service Providers and Investors: On the date of issuance, the instruments are recorded at their fair value as determined using either the Black-Scholes valuation model or Monte Carlo Simulation model.
 
Beneficial Conversion Features of Convertible Securities: Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence.
 
Allowance for Accounts Receivable: We estimate losses from the inability of our distributors to make required payments and periodically review the payment history of each of our distributors, as well as their financial condition, and revise our reserves as a result.
 
Inventory Valuation: All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased.
 
 
 
 
RESULTS OF OPERATIONS
 
COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
 
Research and Development Expenses: Research and development expenses for the three months ended March 31, 2021, decreased to approximately $16,000, from approximately $24,000 to the same period in 2020. The decrease of $8,000, or 33%, was primarily due to a reduction in research and development payroll expenses.
 
Sales and Marketing Expenses: Sales and marketing for the three months ended March 31, 2021, increased to approximately $36,000, from approximately $34,000 to the same period in 2020. The increase of $2,000, or 7%, was primarily due to an increase in sales and marketing payroll expenses.
 
General and Administrative Expense: General and administrative expenses for the three months ended March 31, 2021, increased to approximately $770,000, compared to $184,000 for the same period in 2020. The increase of approximately $586,000, or 319%, was primarily related to higher compensation expenses incurred during the same period and the recording of a charge of $398,000 for warrants issued to Mr. Blumberg for consulting services.
 
Other Income: Other income for the three months ended March 31, 2021, decreased to approximately nil, compared to $1,000 for the same period in 2020. The decrease of $1,000 or 100% was the result of not recording any refunds from prior years for insurance policies.
 
Interest Expense: Interest expense for the three months ended March 31, 2021 decreased to approximately $141,000, compared to $287,000 for the same period in 2020. The decrease of approximately $126,000, or 51%, was primarily related to amortization expense of and interest recorded for the value of the beneficial conversion feature on convertible debt outstanding and amortization of debt issuance costs.
 
Change in fair value of derivative liability: Change in fair value of derivative liability for the three months ended 2021 increased to approximately $88,000, compared to nil for the same period in 2020. The increase of approximately $88,000, or 100%, was primarily related to the change in the value of the derivative liability.
 
Gain from extinguishment of debt: Gain from extinguishment of debt for the three months ended March 31, 2021 decreased to nil, compared to $28,000 for the same period in 2020. The decrease of approximately $28,000, or 100%, was primarily related to debt that had been eliminated from debt exchange agreements in 2020.
 
Fair Value of Warrants Recovery: Fair value of warrants recovery for the three months ended March 31, 2021, decreased to approximately $448,000 compared to fair value of warrants recovery of $3,228,000 for the same period in 2020. The decrease of approximately $2,780,000, or 86% was primarily due to the recording of the debt exchange for the debt to GPB and the elimination of the warrant liability. During 2020, due to significant increases in the fair value price of the Company’s stock the fair value of the warrants recovered increased.
 
Net loss/ Income: Net loss attributable to common stockholders increased to approximately $655,000, or $0.05 per share, for the three months ended March 31, 2021, from net income of $2,716,000, or $0.54 per share, for the same period in 2020. The decrease in the net income of $3,371,000, or 124% was for reasons outlined above. As stated previously, our net income for the three months ended March 31, 2021, and 2020 was primarily realized due to an approximate $448,000 and $3,228,000 fair value of warrants recovery recorded, respectively.
 
There was no income tax benefit recorded for the three months ended March 31, 2021 or 2019, due to recurring net operating losses.
 
LIQUIDITY AND CAPITAL RESOURCES
 
Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants. At March 31, 2021, we had cash of approximately $1.2 million and a negative working capital of approximately $7.3 million.
 
Our major cash flows for the three months ended March 31, 2021 consisted of cash in-flows of $0.3 million from operations, including approximately $0.7 million of net loss and a change in fair value of warrants of $0.5 million, and a net change from financing activities of $0.7 million, which primarily represented the proceeds received from issuance of preferred stock and exchanged outstanding debt.
 
 
 
 
Capital resources for 2021
 
During 2021, we received equity investments in the amount of $2,099,000 and incurred fees due on these investments of $131,000. These investors received a total of 1,421 Series F preferred stock (if the Investor elects to convert their Series F preferred stock, each Series F preferred stock shares converts into 4,000 shares of the Company’s common stock shares) and $678,000 was recorded as subscription receivable for the oversubscribed amounts received for the three months ended of March 31, 2021. The investors for the oversubscribed amount received Series F-2 preferred stock shares during the second quarter of 2021.
 
During 2021, we finalized an investment by Power Up Lending Group Ltd. Power Up invested $132,000, net to us is $125,000, for 153,000 shares of Series G preferred stock.
 
Capital resources for 2020
 
During 2020, we received equity investments in the amount of $1,735,500. These investors received a total of 1,735.5 Series E preferred stock (if the Investor elects to convert their Series E preferred stock, each Series E preferred stock shares converts into 4,000 shares of our common stock shares).
  
During January and April 2020, we received equity investments in the amount of $128,000. These investors received a total of 256,000 common stock shares and 256,000 warrants issued to purchase common stock shares at a strike price of $0.25, 256,000 warrants to purchase common stock shares at a strike price of $0.75 and 128 Series D preferred stock (if the Investor elects to convert their Series D preferred stock, each Series D preferred stock shares converts into 3,000 shares of our common stock shares). Of the amount invested $38,000 was from related parties.
 
On January 6, 2020, we entered into an exchange agreement with Jones Day. Upon making a payment of $175,000, which had not yet occurred, we will exchange $1,744,768 of debt outstanding for: $175,000, an unsecured promissory note in the amount of $550,000; due 13 months form the date of issuance, that may be called at any time prior to maturity upon a payment of $150,000; and an unsecured promissory note in the principal amount of $444,768, bearing an annualized interest rate of 6.0% and due in four equal annual installments beginning on the second anniversary of the date of issuance.
 
On January 8, 2020, we exchanged $2,064,366 in debt for several equity instruments (noted below) that were determined to have a total fair value of $2,065,548, resulting in a loss on extinguishment of debt of $1,183 which is recorded in other income (expense) on the accompanying consolidated statements of operations. We also issued 6,957,013 warrants to purchase common stock shares; with exercise prices of $0.25, $0.75 and $0.20.
 
On June 3, 2020, we exchanged $328,422 in debt from Auctus, (summarized in footnote 10: Convertible Notes), for 500,000 common stock shares and 700,000 warrants to purchase common stock shares. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase common stock shares was $196,818 (based on a $0.281 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $118,396 ($446,818 fair value less the $328,422 of exchanged debt).
 
On June 30, 2020, we exchanged $125,000 in debt (during June 2020, $125,000 in payables had been converted into short-term debt) from Mr. James Clavijo, for 500,000 common stock shares and 250,000 warrants to purchase common stock shares. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase common stock shares was $99,963 (based on a $0.40 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $224,963 ($349,963 fair value less the $125,000 of exchanged debt). After the exchange transaction a balance was due Mr. Clavijo of $10,213 which was paid.
 
On July 9, 2020, we entered into an exchange agreement with Mr. Bill Wells (one of its former employees). In lieu of agreeing to dismiss approximately half of what is owed or $220,000, Mr. Wells will receive the following: (i) cash payments of $20,000 within 60 days of the signing of the agreement; cash payments over time in the amount of $90,000 in the form of an unsecured note to be executed within 30 days of a new financing(s) totaling at least $3.0 million. The note shall bear interest of 6.0% and mature over 18 months; (iii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (ii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid.
 
 
 
 
The following table summarizes the debt exchanges:
 
 
 
Total Debt and Accrued Interest
 
 
Total Debt  
 
 
Total
Accrued
Interest
 
 
Common
Stock
Shares
 
 
Warrants
(Exercise $0.25)
 
 
Warrants
(Exercise $0.75)
 
 
Warrants
(Exercise $0.20)
 
 
Warrants
(Exercise $0.15)
 
 
Warrants
(Exercise $0.50)
 
Aquarius
 $145,544 
 $107,500 
 $38044 
  291,088 
  145,544 
  145,544 
  - 
  - 
  - 
K2 Medical (Shenghuo)3
  803,653 
  771,927 
  31,726 
  1,905,270 
  704,334 
  704,334 
  496,602 
  - 
  - 
Mr. Blumberg
  305,320 
  292,290 
  13,030 
  1,167,630 
  119,656 
  119,656 
  928,318 
  - 
  - 
Mr. Case
  179,291 
  150,000 
  29,291 
  896,456 
  - 
  - 
  896,456 
  - 
  - 
Mr. Grimm
  51,050 
  50,000 
  1,050 
  255,548 
  - 
  - 
  255,548 
  - 
  - 
Mr. Gould
  111,227 
  100,000 
  11,227 
  556,136 
  - 
  - 
  556,136 
  - 
  - 
Mr. Mamula
  15,577 
  15,000 
  577 
  77,885 
  - 
  - 
  77,885 
  - 
  - 
Dr. Imhoff2
  400,417 
  363,480 
  36,937 
  1,699,255 
  100,944 
  100,944 
  1,497,367 
  - 
  - 
Ms. Rosenstock1
  50,000 
  50,000 
  - 
  100,000 
  50,000 
  50,000 
  - 
  - 
  - 
Mr. James2
  2,286 
  2,000 
  286 
  7,745 
  1,227 
  1,227 
  5,291 
  - 
  - 
Auctus
  328,422 
  249,119 
  79,303 
  500,000 
  - 
  - 
  - 
  700,000 
  - 
Mr. Clavijo
  125,000 
  125,000 
  - 
  500,000 
  - 
  - 
  - 
  - 
  500,000 
Mr. Wells4
  220,000 
  220,000 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
 
 $2,737,787 
 $2,496,316 
  241471 
  7,957,013 
  1,121,705 
  1,121,705 
  4,713,603 
  700,000 
  500,000 
 
Ms. Rosenstock also forgave $28,986 in debt.
Mr. Imhoff and Mr. James are members of the board of directors and therefore related parties.
Our COO and director, Mark Faupel, is a shareholder of Shenghuo, and a former director, Richard Blumberg, is a managing member of Shenghuo.
Mr. Wells will also receive 66,000 common share stock options; the details of which are explained above.
  
On January 16, 2020, we entered into an exchange agreement with GPB. Under the terms of this exchange agreement, we will exchange $3,360,811 of debt outstanding as of December 12, 2019 for the following: (1) a cash payment of $1,500,000, (2) 7,185,000 warrants to purchase common stock, previously outstanding, would be exchanged for new warrants to purchase common stock shares at a strike price of $0.20 and (3) a certain amount of preferred stock shares for the remaining balance outstanding upon the final exchange date. On January 8, 2021, we made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On March 31, 2021, the Company recorded this exchange as a subscription receivable and it will issue 2,236 series F-2 preferred stock shares in accordance with the terms of the agreement during the second quarter of 2021.
 
On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On March 31, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matures on January 26, 2021 and accrues interest at a rate of 12% per year.
 
 
 
 
On May 4, 2020, we received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The Company was notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. The Company is planning on appealing the amount forgiven.
 
On May 20, 2020, the Company received a $70,000 loan from Mr. Blumberg, which was paid off in June 2020.
 
On May 22, 2020, we entered into an exchange agreement with Auctus. Based on this agreement we exchanged three outstanding notes, in the amounts of $150,000, $89,250, and $65,000 for a total amount $304,250 of debt outstanding, as well as any accrued interest and default penalty, for: $160,000 in cash payments (payable in monthly payments of $20,000), converted a portion of the notes pursuant to original terms of the notes into 500,000 restricted common stock shares (shares were issued on June 3, 2020); and 700,000 warrants issued to purchase common stock shares with an exercise price of $0.15. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase common stock shares was $196,818 (based on a $0.281 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $118,396 ($446,818 fair value less the $328,422 of exchanged debt). As of March 31, 2021, the not had been paid off.
 
On May 27, 2020, we received the second tranche in the amount of $400,000, from the December 17, 2019, securities purchase agreement and convertible note with Auctus. The net amount paid to us was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The notes maturity date is December 17, 2021 and an interest rate of ten percent (10%).
 
Contingencies
 
Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions in our operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites.
 
The future impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreak will not have a material adverse impact on our operations or future results or filings with regulatory health authorities. The extent of the impact, if any, we will depend on future developments, including actions taken to contain the coronavirus.
 
Off-Balance Sheet Arrangements
 
We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.
 
 
 
 
SIGNATURES
 
In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
GUIDED THERAPEUTICS, INC.
 
 /s/ Gene S. Cartwright
By:Gene S. Cartwright
 President, Chief Executive Officer and
 Acting Chief Financial Officer
 
Date:
 
August 16, 2021